<<<I’ve always considered it odd that MYGN had a single compound being tested for both Alzheimer’s and prostate cancer. I also tend to be suspicious of attempts to resuscitate a mediocre racemic drug by going to a single isomer.>>>
Not to mention fallout from vioxx/aleve etc and being developed as a LT chronic use medication. Plus side, their oncology pipeline seems to be coming along briskly. I'll be keeping a close watch in case the AD outcome is a bust.
Market Data 
Markets 
AI
